^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Ariely (adebrelimab)

i
Other names: SHR-1316, SHR 1316, HTI-1088, HTI-1316, HTI1088, HTI 1088, HTI 1316, HTI1316, SHR1316
Associations
Company:
Jiangsu Hengrui Pharma
Drug class:
PD-L1 inhibitor
Related drugs:
Associations
3d
New P1 trial • Combination therapy
|
Focus V (anlotinib) • epirubicin • Ariely (adebrelimab) • GSK5764227
4d
Neoadjuvant Therapy of HAIC(GEMOX) Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors (clinicaltrials.gov)
P2, N=33, Recruiting, The First Affiliated Hospital with Nanjing Medical University | Initiation date: Mar 2024 --> Dec 2023
Trial initiation date
|
gemcitabine • Lenvima (lenvatinib) • oxaliplatin • Ariely (adebrelimab)
6d
A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma (clinicaltrials.gov)
P1/2, N=90, Recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open • Combination therapy • Metastases
|
CS1002 (ipilimumab biosimilar) • SHR-A2102 • Ariely (adebrelimab)
6d
New P2 trial
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Imfinzi (durvalumab) • gemcitabine • Rozlytrek (entrectinib) • imatinib • 5-fluorouracil • Tyvyt (sintilimab) • Alecensa (alectinib) • Nerlynx (neratinib) • Loqtorzi (toripalimab-tpzi) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • Irene (pyrotinib) • Balversa (erdafitinib) • albumin-bound paclitaxel • irinotecan • Orpathys (savolitinib) • epirubicin • vinorelbine tartrate • Partruvix (pamiparib) • Epkinly (epcoritamab-bysp) • Enweida (envafolimab) • Hetronifly (serplulimab) • Vumon (teniposide) • Ariely (adebrelimab)
11d
Enrollment open
|
Avastin (bevacizumab) • Tyvyt (sintilimab) • Ariely (adebrelimab)
12d
Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC (clinicaltrials.gov)
P2, N=70, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University
New P2 trial
|
docetaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium • Ariely (adebrelimab) • Pegylated rhG-CSF (mecapegfilgrastim)
12d
Enrollment open
|
SHR-A2102 • Ariely (adebrelimab)
14d
Prospective and exploratory clinical study on the efficacy and safety of Adebrelimab combined with chemotherapy as first-line treatment for unresectable locally advanced, recurrent, or metastatic neuroendocrine carcinoma of the digestive tract (ChiCTR2400088905)
P=N/A, N=20, Not yet recruiting, Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine; Renji Hospital affiliated to Shanghai Jiaotong University School of Medi
New trial • Metastases
|
cisplatin • carboplatin • etoposide IV • Ariely (adebrelimab)
14d
Adebrelimab plus interventional and targeted therapy for unresectable hepatocellular carcinoma: a single-arm, real-world study (ChiCTR2400091083)
P4, N=78, Not yet recruiting, The Sixth People’s Hospital of Shenyang; The Sixth People’s Hospital of Shenyang
New P4 trial • Real-world evidence • Real-world
|
AFP (Alpha-fetoprotein) • CRP (C-reactive protein)
|
Ariely (adebrelimab)
14d
New P3 trial • Combination therapy • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Ariely (adebrelimab)
14d
New P2 trial • Metastases
|
5-fluorouracil • oxaliplatin • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • Ariely (adebrelimab)
14d
New P2 trial • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • ALK fusion
|
gemcitabine • Epidaza (chidamide) • Ariely (adebrelimab)
14d
New P2 trial • Metastases
|
5-fluorouracil • Lenvima (lenvatinib) • leucovorin calcium • Ariely (adebrelimab)
14d
New P2 trial
|
PD-L1 (Programmed death ligand 1)
|
AiTan (rivoceranib) • Ariely (adebrelimab)
14d
Efficacy and safety of adebrelimab combined with lenvatinib as neoadjuvant therapy for resectable hepatocellular carcinoma: a randomized controlled open-label phase II study (ChiCTR2400080080)
P2, N=36, Recruiting, The First Affiliated Hospital of Dalian Medical University; The First Affiliated Hospital of Dalian Medical University | Not yet recruiting --> Recruiting
Enrollment open
|
Lenvima (lenvatinib) • Ariely (adebrelimab)
26d
New P2 trial • Metastases
|
cisplatin • albumin-bound paclitaxel • Ariely (adebrelimab)
1m
SHR-8068 combined with adebrelimab and bevacizumab in the treatment of refractory advanced colorectal cancer: study protocol for a single-arm, phase Ib/II study. (PubMed, Front Immunol)
This proof-of-concept study would provide safety and efficacy signals of this novel combination treatment for the MSS CRCs in the late-line setting. And it may offer new insights on the clinical application of dual immunotherapy combined with anti-angiogenic therapy in the MSS CRC.
Clinical protocol • P1/2 data • Journal • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker • Metastases
|
MSI (Microsatellite instability)
|
Avastin (bevacizumab) • Airuituo (bevacizumab biosimilar) • Ariely (adebrelimab)
1m
Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer (clinicaltrials.gov)
P3, N=400, Recruiting, Fudan University | Trial completion date: Sep 2023 --> Dec 2025 | Trial primary completion date: Sep 2022 --> Dec 2025
Trial completion date • Trial primary completion date • Metastases
|
Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • Ariely (adebrelimab)
1m
New P2 trial • Metastases
|
5-fluorouracil • Lenvima (lenvatinib) • leucovorin calcium • Ariely (adebrelimab)
1m
A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma (clinicaltrials.gov)
P1/2, N=90, Not yet recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd.
New P1/2 trial • Combination therapy • Metastases
|
SHR-A2102 • Ariely (adebrelimab)
1m
SHR-A1811-1316: SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in ER Positive/HER2 Low Breast Cancer (clinicaltrials.gov)
P2, N=93, Recruiting, Shengjing Hospital | Not yet recruiting --> Recruiting | Initiation date: Apr 2024 --> Aug 2024
Enrollment open • Trial initiation date • Combination therapy
|
trastuzumab rezetecan (SHR-A1811) • Ariely (adebrelimab)
1m
New trial
|
carboplatin • AiRuiKa (camrelizumab) • albumin-bound paclitaxel • cyclophosphamide • epirubicin • Ariely (adebrelimab)
2ms
New P3 trial
|
Avastin (bevacizumab) • Tyvyt (sintilimab) • Ariely (adebrelimab)
2ms
New P2 trial
|
Ariely (adebrelimab) • HRS-4642
2ms
New P2 trial
|
AiTan (rivoceranib) • etoposide IV • Ariely (adebrelimab)
2ms
New trial • Metastases
|
Fruzaqla (fruquintinib) • Ariely (adebrelimab)
2ms
New P3 trial
|
Ariely (adebrelimab)
2ms
New P2 trial
|
Tecentriq (atezolizumab) • capecitabine • Ariely (adebrelimab)
2ms
New P1/2 trial • Combination therapy • Metastases
|
SHR-A2102 • Ariely (adebrelimab)
2ms
New P2 trial • IO biomarker
|
HRD (Homologous Recombination Deficiency)
|
PD-L1 expression • HRD
|
albumin-bound paclitaxel • AiRuiYi (fluzoparib) • Ariely (adebrelimab)
2ms
Exploratory study on the combination of Adebrelimab and Apatinib in the treatment of PD-1 inhibitor induced liver cancer (ChiCTR2400087077)
P4, N=114, Not yet recruiting, Shandong First Medical University Affiliated Cancer Hospital; Shandong First Medical University Affiliated Cancer Hospital
New P4 trial
|
AiTan (rivoceranib) • Ariely (adebrelimab)
2ms
Adebrelimab (PD-L1) combined with gemcitabine and cisplatin (GP regimen) for unresectable advanced biliary tract cancer (ChiCTR2400087017)
P4, N=144, Not yet recruiting, Shandong Provincial Hospital Affiliated to Shandong First Medical University; Shandong Provincial Hospital Affiliated to Shandong First Medical Univer
New P4 trial • Metastases
|
cisplatin • gemcitabine • Ariely (adebrelimab)
2ms
Adebrelimab plus chemotherapy as first-line treatment in advanced first-line non-small cell lung cancer:a single arm ,phase 2 trial. (ChiCTR2400087166)
P4, N=42, Not yet recruiting, Taihe hospital,Affiliated hospital of hubei university of medicine; Taihe hospital
New P4 trial • Metastases
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • ALK translocation
|
Ariely (adebrelimab)
2ms
A single arm, prospective, exploratory study of Adebrelimab combined with lenvatinib and hepatic arterial infusion chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma (ChiCTR2400087024)
P2, N=25, Not yet recruiting, Shandong First Medical University Affiliated Cancer Hospital; Shandong First Medical University Affiliated Cancer Hospital
New P2 trial
|
Lenvima (lenvatinib) • Ariely (adebrelimab)
2ms
New P2 trial
|
cisplatin • AiTan (rivoceranib) • capecitabine • etoposide IV • Ariely (adebrelimab)
2ms
New P2 trial
|
Loqtorzi (toripalimab-tpzi) • Ensacove (ensartinib) • Qi Xinke (iruplinalkib) • Semena (befotertinib) • bozitinib (APL-101) • Ariely (adebrelimab) • SHR-A1921
2ms
An open, single-arm study of high-intensity focused ultrasound (HIFU) combined with Adebrelimab and XELIRI for the second-line treatment of locally advanced or metastatic pancreatic cancer (ChiCTR2400087021)
P2, N=20, Not yet recruiting, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital); The First Affiliated Hospital of Nanjing Medical University
New P2 trial • Metastases
|
Ariely (adebrelimab)
2ms
New P2 trial • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Rituxan (rituximab) • Ariely (adebrelimab)
2ms
New P2 trial • Combination therapy
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
Focus V (anlotinib) • Ariely (adebrelimab)
2ms
Adebrelimab and Chidamide plus Gemcitabine as first-line treatment for advanced and metastatic pancreatic cancer patients (P-reCise/SCOG-P001): An exploratory, phase 2 trial. (ChiCTR2400079609)
P2, N=32, Recruiting, First affiliated hospital of Soochow university; First affiliated hospital of Soochow university | Not yet recruiting --> Recruiting | Phase classification: PN/A --> P2 | N=90 --> 32 | Initiation date: Jan 2024 --> Aug 2024
Enrollment open • Phase classification • Enrollment change • Trial initiation date • Metastases
|
gemcitabine • Epidaza (chidamide) • Ariely (adebrelimab)
2ms
New P2 trial
|
carboplatin • albumin-bound paclitaxel • Ariely (adebrelimab)
2ms
New P2 trial
|
AiRuiKang (dalpiciclib) • Ariely (adebrelimab)